Can RNA editing patterns tell us something useful about a patient's disease?
Yes, and this is where the human evidence is strongest. Multiple large-scale studies of patient tissues show that the level and location of RNA editing events are consistently linked to cancer prognosis and treatment response. In lung adenocarcinoma, researchers analyzed over 10,000 RNA editing sites across 440 patients and built a prognostic model using six specific editing sites; higher risk scores were significantly associated with worse overall survival [5]. Another study of 486 lung adenocarcinoma patients confirmed that global RNA editing levels were elevated in tumors and highly variable between patients, and identified a new molecular subtype (EC3) linked to the poorest prognosis—validated with an area under the curve of 0.93, meaning it distinguished this subtype with very high accuracy [10].
In gastric cancer, a study of 104 patients developed a 50-site RNA editing signature that predicted response to platinum-based chemotherapy with 84% accuracy; patients with higher editing levels had better overall response [9]. This is not just a cancer phenomenon: a 2022 study across 49 human tissues identified over 30,000 genetic variants that control RNA editing levels (edQTLs), and these were significantly enriched in genome-wide association study signals for autoimmune and inflammatory diseases like Crohn's disease and rheumatoid arthritis [6]. The evidence from these human tissue studies is robust and consistent across multiple cancer types and inflammatory conditions.
Has anyone actually fixed a disease-causing RNA in a human patient yet?
Not yet in a patient, but the tools have been shown to work in human cells in the lab, and some are moving toward clinical trials. One study used an evolved bacterial enzyme (TadA8e) to perform site-specific RNA editing in human lung fibroblasts, correcting a defect in the IRF6 gene that causes Van der Woude syndrome—a genetic disorder. They restored protein expression from 12.3% to 36.5% of healthy levels [2]. Another approach used circular RNA-mediated prime editing in human cells to achieve editing efficiencies up to 40.75% at specific genomic sites [1]. A 2025 review notes that initial clinical advancements are already demonstrating the potential of ADAR-mediated RNA editing in treating human diseases, though it does not name specific completed trials [8].
The key caveat is that all of these are still in the preclinical or early translational phase. The tools work in cultured human cells, but delivering them safely and specifically to the right tissues in a living patient remains a major hurdle. A 2026 review highlights that delivery efficiency, tissue specificity, and immunogenicity are core bottlenecks that must be solved before these therapies can become routine [7]. So the human evidence for therapeutic editing is strong at the cellular level, but the leap to the clinic has not yet been made.
What are the safety risks that could slow down RNA editing therapies?
Two major safety concerns stand out from the evidence: off-target editing and immune reactions to the editing machinery. A 2024 study found that while their DECOR system achieved on-target activity similar to existing platforms, it still had off-target effects—though they were 88% lower than other methods [2]. High-fidelity versions reduced off-target effects to near-baseline levels, suggesting this problem is solvable but not trivial.
A more surprising finding came from a 2022 study that tested blood from healthy donors for immune responses to Cas13d, a popular RNA-editing enzyme. They found that most donors had pre-existing antibodies and T cells reactive to Cas13d, comparable to responses seen against Cas9 proteins already in clinical use [4]. This means that even if you deliver the editing tool perfectly, the patient's immune system might attack it, reducing effectiveness or causing inflammation. This is a real-world human data point that tempers the hype: the immune system has already seen these bacterial proteins, likely from prior exposure to gut bacteria, and may mount a response.
About These Sources
This answer is built on 10 peer-reviewed studies — published from 2021 to 2026, 5 from 2024 or later, 8 in Q1 journals, collectively cited 362 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 75 papers retrieved from a database of over 500 million.
Sources used in this answer
Prime editing using CRISPR-Cas12a and circular RNAs in human cells
Developed circular RNA-mediated prime editing (CPE) systems using Cas12a in human cells, achieving editing frequencies up to 40.75% without positive selection, and demonstrated low-efficiency editing of up to four genes simultaneously.
Programmed RNA editing with an evolved bacterial adenosine deaminase
Developed DECOR, an evolved bacterial TadA8e enzyme for RNA editing in human lung fibroblasts, achieving on-target activity similar to ADAR platforms with 88% lower off-target effects, and rescued IRF6 protein expression from 12.3% to 36.5% of healthy levels.
Circular RNA-mediated inverse prime editing in human cells.
Developed circular RNA-mediated inverse prime editors (ciPEs) that edit upstream of the nickase cleavage site, achieving editing efficiencies from 0.1% to 24.7%, and up to 55.4% with Rep-X helicase optimization in human cells.
Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans
Found pre-existing antibodies and T cell responses to Cas13d in most healthy donors, comparable to responses against Cas9 proteins, with T cells producing inflammatory cytokines IFN-γ, TNF-α, and IL-17.
Clinical relevance of RNA editing profiles in lung adenocarcinoma
Evaluated 10,441 A-to-I RNA editing sites in 440 lung adenocarcinoma patients and built a prognostic model using six editing sites; higher risk scores were significantly associated with worse overall survival.
RNA editing underlies genetic risk of common inflammatory diseases
Identified 30,319 cis-RNA editing QTLs across 49 human tissues; these were significantly enriched in GWAS signals for autoimmune and inflammatory diseases, and disease risk variants were associated with reduced editing and induced interferon responses.
DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects
Review comparing DNA and RNA editing tools, highlighting that delivery efficiency, tissue specificity, genotoxicity, and immunogenicity remain core bottlenecks for in vivo therapeutic applications.
Emerging clinical applications of ADAR based RNA editing
Review noting that initial clinical advancements are demonstrating the potential of ADAR-mediated RNA editing in treating human diseases, with ongoing innovations in guide RNA design and delivery technologies.
“3G” Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy
Identified a 50-site RNA editing signature (GCRE) in 104 advanced gastric cancer patients that predicted chemotherapy response with 84% accuracy; higher editing levels correlated with better overall response.
Identification of A-to-I RNA editing profiles and their clinical relevance in lung adenocarcinoma
Evaluated 19,316 RNA editing sites in 80 lung adenocarcinoma patients (plus 486 from TCGA), found elevated editing in tumors, and identified a new molecular subtype (EC3) with poorest prognosis, validated with AUC of 0.93.